Protara Therapeutics, Inc.
Income Statement
| Line Item | Sep 2014 |
|---|---|
| Revenue | $2.9M |
| Cost of Revenue | — |
| Gross Profit | — |
| Gross Margin | — |
| Operating Expenses | |
| Research & Development | $1.8M |
| SG&A Expense | $1.0M |
| Operating Income | $134.0K |
| Operating Margin | 4.5% |
| Interest Expense | $-10.0K |
| Pretax Income | — |
| Income Tax Expense | $0 |
| Net Income | $-5.2M |
| Net Margin | -175.7% |
| EPS (Basic) | $-15.50 |
| EPS (Diluted) | $-15.50 |
| Shares Outstanding (Basic) | 481.2K |
| Shares Outstanding (Diluted) | 481.2K |
| Dividends Per Share | — |